Skip to main content
. 2021 Jan 28;62(7):956–960. doi: 10.2967/jnumed.120.245290

FIGURE 2.

FIGURE 2.

Flow cytometry analysis of CRTpep binding to ecto-CRT after immunogenic and nonimmunogenic drug treatment in CT26 cells. (A) Flow cytometry analysis of CRTpep binding to ecto-CRT after immunogenic and nonimmunogenic drug treatment in CT26 cells. Binding of FITC-CRTpep to ecto-CRT in CT26 cells after 2 and 4 h of anticancer drug (immunogenic and nonimmunogenic) treatment was determined by flow cytometry. Percentage cellular uptake was based on detected mean fluorescence levels of untreated control cells. After anticancer drug treatment, CT26 cells were preincubated with CRTpep (200 μM) for 1 h, followed by incubation with FITC-CRTpep (2 μM), and then were subjected to flow cytometry to detect uptake using fluorescence generated by ecto-CRT. (B) Quantitative assessment of binding of FITC-CRTpep to ecto-CRT in CT26 cells after 2 and 4 h of anticancer drug (immunogenic and nonimmunogenic) treatment that was determined by flow cytometry. Data are mean (±SD) fluorescence level. ***P < 0.001 (n = 3). DXR = doxorubicin; GEM = gemcitabine; MTX = mitoxantrone; ns = not significant; OXP = oxaliplatin.